mai 30, 2023
The Patented Medicine Prices Review Board estimates 5.7 million Canadians have diagnosed and undiagnosed diabetes and another 6 million are likely prediabetic. The cost burden of diabetes in Canada is around $29 billion annually. Other findings include:
- Antidiabetic drug growth outpaced the overall drug market, doubling the market share for these drugs from 4.2% to 7.9% (2012 to 2021);
- New-generation treatments were the main driver of growth;
- Canadian prices were higher than PMPRB comparator countries; and
- Biosimilar policies led to more switching.
Related:
Les dépenses en médicaments antidiabétiques au Canada ont dépassé celles de l'ensemble du marché des médicaments - Conseil d'examen du prix des médicaments brevetés
Lire l'article